Reata Pharmaceuticals, focusing on rare disease therapies, saw a boost as the FDA greenlit its Friedreich's ataxia treatment, Skyclarys, leading to a surge in its shares in March.
MoonLake Immunotherapeutics focuses on sonelokimab, a promising treatment for inflammatory diseases. The stock has gained 448.2% in 2023, buoyed by high expectations on Wall Street for the drug.